RT Journal Article
SR Electronic
T1 588 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: post hoc analysis of the costs of grade ≥3 adverse events (AEs)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A668
OP A669
DO 10.1136/jitc-2023-SITC2023.0588
VO 11
IS Suppl 1
A1 Lubinga, Solomon J
A1 Payer, Tilman
A1 Gregg, Meghann
A1 Lee, Lydia
A1 Allonby, Odette
A1 García-Fernández, Llenalia
A1 Hurteau, Jean
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A668.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.